
First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

Henkel buys FDCA from Avantium NV
From next year, Henkel will buy FDCA to bring environmentally friendly high-performance polyurethane adhesives for electronic applications to market....

Free sugar linked to higher cardiovascular disease
The findings of a group headed by Rebecca Kelly at University Oxford (doi: 10.1186/s12916-022-02712-7) strengthen the evidence for the global...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...

€72M from Novo´s REPAIR Impact Fund for Group B Streptococcus vaccines
Group B Streptococcus (GBS) colonises globally about 15-25% of women and can cause life-threatening infections in newborns during the first months of...

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

Germany’s Curevac offers common shares
In addition to these ordinary shares, Tübingen-based CureVac is enticing investors to give up another 15% of the number of ordinary shares under the...